Jefferies Remains Unchanged On Danaher (DHR)

Jefferies remained unchanged on its Danaher DHR Buy rating and $54 price target in a research report published today. In the report, Jefferies states, "DHR's dramatic portfolio evolution has escalated its secular organic revenue growth and ROIC profiles while reducing the enterprise's operational volatility. Its considerable exposure to favorable dynamics underway in Life Sciences, Diagnostics and Dental markets is a key investment merit, in our view." Shares of Danaher were at $46.63 in after hours trading at the time of posting, down 0.04% from Thursday's market close.